Rethinking end-points for bone-targeted therapy in advanced cancer
| Autor: | Susana Gomez Garcia, Eitan Amir, Mark Clemons |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Endpoint Determination medicine.medical_treatment Bone Neoplasms Placebo Targeted therapy 03 medical and health sciences 0302 clinical medicine Quality of life Internal medicine medicine Humans 030212 general & internal medicine Survival analysis Bone Density Conservation Agents Diphosphonates business.industry Survival Analysis Clinical trial Denosumab 030220 oncology & carcinogenesis Physical therapy Quality of Life Regression Analysis business medicine.drug |
| Zdroj: | European journal of cancer (Oxford, England : 1990). 63 |
| ISSN: | 1879-0852 |
| Popis: | The principal objective for any medical therapy is to improve either the duration of life and/or its quality. Metastases in bone can lead to clinically defined events termed skeletal-related events (SREs) which are a quantifiable measure of skeletal morbidity. Avoidance and/or delay of SREs have become the principal objective in trials exploring the efficacy of bone-targeted therapy in patients with skeletal metastases. Despite reductions in the frequency or rate of SRE occurrence, trials of bone-targeted therapy have failed to show any effect on either progression-free or overall survival when compared with placebo or other bone-targeting agents. Similarly, trials of bone-targeted therapy have not shown consistent effects on quality of life. The validity of SRE-based primary outcome measures in cancer clinical trials is therefore, questionable. More novel end-point selection for trials of bone-targeted therapy seems warranted. Composite measures comprising occurrence of symptomatic skeletal events and patient reported outcomes may be an effective solution and warrants further investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect